Independent Bio-Assay Overview
December 11, 1998

Salt Lake City, UT - 4Life Research, a Provo, Utah research and development company released its latest assaying and testing for its new 4Life Transfer Factor™ product.

Transfer factor is a scientifically recognized delivery system for transferring immune system advantages from one species to another. In the patented process licensed to 4Life, immune factors are generated in cows and then "transferred" as a nutritional supplement to humans. Products manufactured incorporating the process are anticipated by industry experts to be the "next wave" of nutritional supplementation, operating in the newly defined area of "structure/function" claims. Dr. William Hennen, who is one of the world authorities on transfer factor, says of the science and technology: "Transfer factor is a material that has the ability to modulate the immune system. 4Life Transfer Factor™ contains both materials that help the immune system respond more effectively and materials to make sure the immune system is not over-responding."

4Life's founder and president, David Lisonbee said, "4Life has an agreement with the patent inventors to market transfer factor. United States Patent No. 4,816,563, issued on March 28, 1989, is licensed to 4Life. This patent describes the proprietary process used by 4Life to create its unique Transfer Factor™.

The only patent 4Life is aware of which identifies transfer factor in colostrum, the process for obtaining transfer factor from colostrum and whey, and the patented method "to further concentrate and/or purify transfer factor" from colostrum, is the one licensed to 4Life. It is United States Patent No. 4,816,563.

Laboratory Testing of 4Life's Transfer Factor™
According to William Hennen, Ph.D., Vice President of Research and Development at 4Life, "Each and every batch of Transfer Factor™ is tested by an independent laboratory with established, documented credentials in assessing for transfer factor activity. Very few laboratories have the experience or credentials to assay for TF activity. We go to great lengths to assure the quality of transfer factor in our product. This is the reason our distributors are consistently having such great success with Transfer Factor™. From infants to the elderly, reports keep coming in every day with results that have matched or exceeded our every expectation. Transfer factor has nearly 50 years of research and over 3,000 clinical studies and scientific papers proving its existence and effectiveness. Our licensed patent proved for the first time that transfer factor exists in colostrum and that it can be successfully extracted and assayed."

Independent Laboratories Show Transfer Factor Activity in 4Life's Transfer Factor™
Independent laboratory tests clearly indicate that 4Life's Transfer Factor™ shows significant transfer factor activity equal to the effectiveness of the standard vaccine.
The biological and chemical testing laboratory, BioLogics Inc. states the following regarding 4Life's Transfer Factor™:

"BioLogics Inc. has completed testing the preparations of bovine colostrum you sent for evaluation for TF (transfer factor) activity. Each preparation was evaluated for TF activity using a mouse foot- pad assay which measures delayed-type hypersensitivity (DTH). The results are shown below. A preparation was considered active if it induced significant DTH (p<0.005 or better) as compared to the response to [an] antigen in control mice which were naive (not treated with TF)."

Preparation tested	Transfer Factor Presence	Transfer Factor Active
Vaccinated Controls Mice injected with standard antigen vaccine	0.01>P>0.001	YES (P<0.01) Very Active
Colostrum Fraction Normally fractionated colostrum	0.20>P>0.10	NO (P>0.10) Failed
4Life Transfer Factor™ Patented extract of colostrum	0.01>P>0.001	YES (P<0.01) Very Active

"Further, it is critical to understand that a proper transfer factor assay includes both a zero-point standard and a high-end standard (to set the span of the scale.) The zero-point standard accounts for the nutritional value of the transfer factor preparation and is represented by the fractionated colostrum listed in the second row above. A vaccinated control is the GOLD STANDARD for establishing the high-end of the immunological scale as represented in the first row.
As was clearly shown, 4Life's Transfer Factor™ was not only measurably more potent than the normal colostrum of the second row, it was equal to the vaccine standard in causing a strong immune response," stated Dr. Hennen.

Top Transfer Factor Researcher Tests 4Life's Transfer Factor™
One of the world's leading TF researchers has also tested 4Life's Transfer Factor™ using a mouse foot-pad assay.
"Three different colostrum extracts were tested, one of which was 4Life's Transfer Factor™. 4Life's Transfer Factor™ tested highest in TF activity of any of the samples tested."

Molecular Weight Laboratory Testing of 4Life's Transfer Factor™
An independent laboratory experienced in molecular weight analysis tested samples of 4Life's Transfer Factor™ and found it to contain exactly what 4Life claims it contains: Molecules in the molecular weight of 10,000 daltons or less. Bay Bioanalytical Laboratory, Inc. stated in their report:
"[We] have reviewed the analysis of [4Life's] Transfer Factor performed in our laboratory using HPLC and a size exclusion column coupled with a light scattering, refractive index and a UV detector. Based on our analysis we can conclude [that] the analyzed fraction is composed primarily of molecules below 10,000 [daltons] molecular weight."
Bay Bioanalytical Laboratory, Inc.

Transfer Factor Plus™: An In Vivo Study
27 April, 2000

Purpose of Study: To determine the effectiveness of natural products in increasing the function of Natural Killer (NK) cell activity in chronic illnesses. In this study persons suffering from Fibromyalgia were chosen to take part in an in vivo study.

Background: It is felt that chronic illnesses represent immune system failures in most instances, particularly in the Fibromyalgia Syndrome. There have been many published reports of low Natural Killer cell activity or function in persons with Fibromyalgia.

Natural Killer Cells: Natural Killer cells are the first line of defense in our innate immune systems. Natural Killer cells are lethal lymphocytes containing granules filled with potent chemicals. They do not need to recognize a particular antigen but rather attack "nonself". They protect against and target tumor cells and a wide variety of infectious microbes, particularly virally infected cells. NK cells kill by binding to their targets and delivering a lethal burst of chemicals that produce holes in the target cell's membrane. Fluids seep in and leak out and the cells burst and die.

Patient Selection: Nine patients were enrolled in the study who had been diagnosed with Fibromyalgia and who weren't taking any known immune stimulants at the time of enrollment.

Nutritional Supplements Used in Study:*
Name: Transfer Factor Plus™	Dosage: One, twice daily, days 1-10 Two, twice daily, days 11-20
Fibro AMJ™ Daytime Formula	Two, three times daily
Fibro AMJ™ Nighttime Formula	One, nightly
Choice 50™ Antioxidants	One, twice daily

Length of Study: Blood work was drawn on day 1 before the beginning of the use of the products and on day 21 after using the products for 20 consecutive days.

Methodology:The patients' blood was drawn and peripheral blood mononuclear cells were isolated and NK cell activity was assessed by a variation of the 51Cr release assay. The target cells were live K562 erytholeukemic cells. NK cytolytic activity was calculated at the baseline of day 1 and on the 21st day.

Patient NK Results

	4/02/00	4/23/00
Name of Patient	NK Assay Baseline %	NK Assay Final %
JB	13	29
DS	13	19.5
CW	13	31.5
PM	6	25.5
LG	9	25.5
SR	10	25
BM	6.5	27
JK	8.5	23.5
MW	11	35.5
Mean of Results	10	26.9

Comment: If a person has a Natural Killer cell activity below 20%, they are felt to be more susceptible to acute or chronic illnesses, or to have a compromised ability to recover from existing illnesses. All of the nine volunteers had NK cell function of less than 20% activity with a range of 6 to 13%, and an average of the group of 10% activity.

Summary:All of the nine patients had significant increases in Natural Killer cell activity. The levels after 20 days on the products now ranged from 19.5% to 35.5% with an average of 26.9% or 269% of baseline. Prior in vitro testing of Transfer Factor Plus™ revealed an increase in activity of 248%. Other products were used in addition to Transfer Factor Plus™ to address other issues associated with Fibromyalgia (Fibro AMJ Daytime and Nighttime Formulas and Choice 50 antioxidants). These products are not known to have an effect on natural killer cell activity. We believe the significant immunostimulatory effect was achieved through the use of Transfer Factor Plus™.

Rob Robertson, M.D

*Products provided by 4Life™ Research
2066 South 950 East, Provo, UT 84606

4Life Research has been working with Russia's Top Scientists such as -
Dr. Victor Tutelian
4Life Welcomes Dr. Tutelian - Click Here!
The following 4 studies were performed in Russia.

ABSTRACT
Transfer Factor in Dermatovenerology
S.G. Luikova, O.B. Nyemchanyinova, E.V. Chernikova, Iu.P. Gichev
Novosibirsk State Medical Academy;
Research Center for Clinical and Experimental Medicine SD RAMS, Novosibirsk

INTRODUCTION: According to current theories psoriasis is complicated by recurrent herpes infection, which brings about the suppression of interferon production and suppressed T-cellular immunity. This necessitates carrying out the immune status correction in addition to specific antiviral therapy. With this in mind we undertook the evaluation of the clinical effectiveness of transfer factors in this group of patients with psoriasis who also suffer from recurrent genital herpes.

OBJECTIVE: The aim of this investigation was to study the effects of enhanced transfer factors in a complex treatment of patients with psoriasis and recurrent genital herpes. METHODOLOGY 1: This study was initially conducted with 8 patients with exudative psoriasis, 5 children age 9-14 and 3 adults, ages 19-46. Four of these patients were manifesting dermatosis for the first time. All patients had widely distributed eruptions. Since traditional methods of treatment were not effective enough, we added enhanced transfer factors from bovine colostrum. The product was administered according to the following scheme: 4 capsules daily for 14 days and then 4 capsules twice a week for 14 days. The product was obtained from 4Life Research, USA. The clinical effectiveness of the product was evaluated. RESULTS 1: By the end of the course of treatment 7 patients demonstrated a marked improvement of skin condition. We prolonged treatment in only one patient for an additional two weeks. This patient has suffered from psoriasis since 1998 and exhibited signs of arthropathy. METHODOLOGY 2: We continued the study with an additional 9 patients, ages 18-38, with disease duration of 6 months to 5 years and that had suffered from severe (only several days to six weeks remission) or moderate severity (2 to 3 months remission) courses of the disease. During the recurrent course of the disease the majority of patients received antiviral (acyclovir) and non-specific immunomodulating drugs, biogenic stimulators and others, which in the majority of cases resulted in only a slight prolongation of the remission period. Enhanced transfer factors were given as a monotherapy to the patients during periods of genital herpes relapse according to the following scheme: 4 capsules daily for 2 weeks, then 4 capsules 3 times a week and in the following 2 weeks 4 capsules twice a week. The therapeutic effectiveness of the product was evaluated according to the duration of remission and the duration and severity of relapses as compared with the course of treatment without the use of transfer factors. RESULTS 2: Seven of nine patients receiving transfer factors demonstrated stable antirecurrent effects. Two patients had a relapse on the 2nd and the 4th weeks of the treatment, but it was of an abortive nature and did not affect quality of life. Pain acuteness in these instances was less pronounced than during the previous relapses. In the following 6 weeks the patients demonstrated stable clinical remission. CONCLUSION: We concluded that the use of enhanced transfer factors in patients with psoriasis and recurrent genital herpes gave improved clinical results which prompts the expediency of further clinical studies.

ABSTRACT
Usage of transfer factors in treatment of HIV-Infected Patients
Granitov V.M., Karbysheva N.V., Sultanov L.V., McCausland C., Oganova E.
The Altay State Medical University;
The Altay Regional Center for Prophylaxis and Treatment of AIDS, Russian Federation

INTRODUCTION: Included in this study were 25 HIV-infected patients (20 male and 5 female), ages 19 to 56 (15 patients ages 21-25). Individuals were classified according to V.I. Pokrovskys classification (1989) for HIV-infection. Eight (8) patients were diagnosed to have stage 2B, thirteen (13) patients were stage 2C, three (3) patients were stage 3A and one (1) was stage 3B. Infection periods were as follows: nine (9) patients were infected 1 year ago, four (4) were 2 years ago, four (4) were three years ago, six (6) were 5 years ago and two (2) were 6 years ago. OBJECTIVE: The purpose of this study is to serve as an initial trial in evaluating the effects of enhanced transfer factors supplementation on HIV-infected patients. METHODOLOGY: The experimental group (15 patients), who did not receive antiretroviral or immuno-correcting therapy, received enhanced transfer factors provided by 4Life Research, USA. They were administered one capsule twice a day for 7 days. The control group (10 patients) consisted of HIV-infected patients taking cycloferon in the following dosage schedule: 1st, 2nd, 4th, 6th, 8th, 10th, 12th and 14th days. Before treatment and 7 to 10 days after the treatment an evaluation was carried out to access the immune status of the patient groups and to determine cytokine (interleukin 1b (IL-1b), tumor necrosis factor (TNF-a) and g-interferon (IFN-g) levels. RESULTS: In the experimental group, it was found that after treatment with enhanced transfer factors there was an increase of lymphocytes in 13 patients, an in crease of CD3 cells in 15 patients, an increase of CD4 cells in 14 patients and an increase in CD8 cells in 12 patients. Immuno-regulating index (IRI) persisted on the same level in 3 patients was increased in 10 patients and decreased in 7 patients. IgG was reduced in 16 patients and IgM was within normal limits in all patients. An increase of IL-1b and IFN-7 was noted in all patients treated with transfer factors. Circulating Immune Complex (CIC) levels dropped to normal levels in 10 of the patients. In the control group an increase of lymphocytes was noted in only 3 patients. A decrease of CD3, CD4 and CD8 cells was noted in 6 patients. IRI persisted on the same level or decreased. CIC levels dropped to normal in 3 patients, increased in 6 patients, there was no change in 1 patient. The occurrence of increases and decreases of IgG were equal. CONCLUSION: We conclude that transfer factors therapy considerably improves the immune status of HIV-infected patients and can be recommended in combating the pathogenesis of the disease. Further studies are needed to determine optimal therapy, the necessity to repeat courses of the treatment and the frequency of therapy needed.

ABSTRACT
Enhanced Transfer Factors in the Complex Treatment of Patients with Opisthorchiasis
N.V. Karbysheva, L.V. Sultanov, S.I. Belykh, C. McCausland, E.Oganova
Altay State Medical University, Barnaul Russian Federation;
Altay Center for AIDS Prevention and Control

INTRODUCTION: Opisthorchiasis is one of the most prevalent and socially significant helminthisms in Russia. The Western Siberia Region is known to be among the most dangerous locations of opisthorchiasis in the world. The infection rate among the local population in this area is considered to be 70-80% and perhaps as high as 90%. Therefore, there is an urgent need to find a more effective treatment. Many investigators have expressed the necessity of correcting immune reaction imbalances in opisthorchiasis patients. Immuno-rehabilitation is recommended as part of the complex therapy needed in the treatment of opisthorchiasis, but the authors have not singled out a definite group of medicines among a vast number of immune modulators. OBJECTIVE: To evaluate the effectiveness of enhanced transfer factors (provided by 4Life Research, USA) in the treatment of patients with chronic opisthorchiasis. METHODOLOGY: The study examined 94 patients that were grouped as follows: Group 1 (experimental) included 50 patients who received enhanced transfer factors. Group 2 (control) included 44 patients. In order to evaluate the obtained data we also examined 75 opisthorchiasis-free donors. All patients underwent antihelminthic therapy with bilthricide (Bayer company) according to the following scheme: 75mg/kg body weight three times orally per day. Of these, 50 patients (Group 1) received 2 capsules of enhanced transfer factors 3 times daily for 7 days after antihelminthic therapy. The 44 patients in Group 2 were matched to patients in Group 1 by sex, age and clinical manifestations and received bilthricide therapy. In both groups all the parameters to be investigated were defined and measured before therapy, 2 weeks after beginning therapy and 3 months after discontinuation of therapy. Follow-up was conducted with all patients at 6 months. RESULTS: The follow-up revealed that enhanced transfer factors is well tolerated. Patients in Group 1 had no occurrence of asthenovegetative syndrome or increase in the frequency of intensified pain in the right hypochondrium, which is common after bilthricide treatment. Three months after treatment the morbid manifestations of hepatobililary system were observed only in Group 2. Arthralgia and vasculitis occurred in both groups, but the number of such patients decreased in Group 1 and remained unchanged in Group 2. Immuno-correction was manifested in the highest degree 6 months after treatment. All 12 patients with arthralgia in Group 1 experienced convalescence while in Group 2 only 4 of 13 convalesced. Of those in Group 1 with vasculitis 7 of 9 convalesced, whereas, none of the 6 with vasculitis in Group 2 convalesced. CONCLUSION: The use of enhanced transfer factors in the complex therapy of opisthorchiasis resulted in more complete patient convalescence within the six month period. The results of the study demonstrate the clinical and immunological effectiveness of enhanced transfer factors. Its use promotes activation of the monocyte-macrophage link, which is defined by the increase of IL-1b, TNF-a and especially IFN-g concentration leading to the induction of the second phase immune response with the formation of the specific protective immunity. Immuno-rehabilitation by enhanced transfer factors following dehelminthization with bilthricide promotes quick elimination of opisthorchiasis antigens thus preventing the development of other immunopathologic processes. It also promotes elimination of chronic opisthorchiasis and generally results in complete and early recovery. In our view it is advisable to use enhanced transfer factors in the complex therapy of patients with this invasion.

ABSTRACT
Effectiveness of transfer factors (TF) in the Treatment of Osteomyelitis Patients
Professor A.V. Rak, Departmental Head of Traumatology, Orthopedics and Field Surgery,
and Professor V.A. Dadali, Departmental Head of Biochemistry
St. Petersburg State Medical Academy, Russian Federation

INTRODUCTION: The experience of studying chronic osteomyelitis, one of the most protracted and sever infections, testifies to the leading role of free radical and peroxide oxidation reactions with lipids and proteins in the pathogenic mechanisms of the disease and immune deficiency formation in patients. Being a purulent (pus forming) inflammatory process, osteomyelitis is characterized by intensified free radical and peroxide processes, disturbed membrane function and boy intoxication. OBJECTIVE: The aim of this investigation was to study the TF products effectiveness in a complex treatment of chronic osteomyelitic patients. The transfer factors product was obtained from 4Life Research, USA. METHODOLOGY: Patients with different forms of osteomyelitis were divided into 2 groups: experimental (20 patients) and control (13 patients). The standard method of treatment was comprised of surgery with the aim of removing the purulent infection and administering wide spectrum antibiotics (gentamycin, ampiox, etc.) in the postoperative period. The experimental group (20 patients) in addition to surgery and standard antibacterial treatment received 2 capsules of TF 3 times daily. The control group (13 patients) matched by nosological classification, sex and age received conventional therapy. Laboratory analyses and clinical investigations were carried out before, one week after surgery and one month after the complex treatment and included clinical, biochemical and immunological evaluations. RESULTS: The use of transfer factors in the complex treatment of osteomyelitis proved beneficial in the treatment of disease. The product was found to increase the effective ness of the ascorbate and thio-disulfide antioxidant system (AOS) links and normalize functional activity of the AOS enzymes. In complex osteomyelitis the use of the TF product was shown to decrease peroxidation of lipid and protein structures and to product a membrane-stabilizing effect. Changes in the humoral immunity link, characterized by an increased product of IgA, and stimulation of the phagocytic immunity link, with out a noticeable increase of circulating immune complex (CIC) level, were also established. CONCLUSION: The data obtained showed that in osteomyelitis enzymatic and low molecular antioxidant links of the body defense system as well as cellular systems membranous mechanisms were the first elements to respond positively to TF effects thus forestalling the disease by development of beneficial immune responses. The improvement of these values in combination with the pronounced positive dynamics of the immune system leads us to conclude that even in cases of severe infection, as in osteomyelitis, TF can be recommended as an addition to the conventional treatment. It is also useful to prolong the period of product administration to further improve the indices of the protective mechanisms and, most of all, to improve the patients immunity.

Dr. See Abstracts

Immunol Invest 2002 May;31(2):137-53

Increased tumor necrosis factor alpha (TNF-alpha) and natural killer cell (NK) function using an integrative approach in late stage cancers.

See D, Mason S, Roshan R.

Center for Advanced Medicine, Encinitias, California 92024, USA.

Natural products may increase cytotoxic activity of Natural Killer Cells (NK) Tumor Necrosis Factor alpha (TNF-alpha) while decreasing DNA damage in patients with late-stage cancer. Pilot studies have suggested that a combination of Nutraceuticals can raise NK cell function and TNF-alpha alpha activity and result in improved clinical outcomes in patients with late stage cancer. The objective of the study is to determine if Nutraceuticals can significantly raise NK function and TNF levels in patients with late stage cancer. After informed consent was obtained, 20 patients with stage IV, end-stage cancer were evaluated (one bladder, five breast, two prostate, one neuroblastoma, two non-small cell lung, three colon, 1 mesothelioma, two lymphoma, one ovarian, one gastric, one osteosarcoma). Transfer Factor Plus (TFP+, 3 tablets 3 times per day), IMUPlus (non denatured milk whey protein, 40 gm/day); Intravenous (50 to 100 gm/day) and oral (1-2 gm/day) ascorbic acid; Agaricus Blazeii Murill teas (10 gm/day); Immune Modulator Mix (a combination of vitamin, minerals, antioxidants and immune-enhancing natural products); nitrogenated soy extract (high levels of genistein and dadzein) and Andrographis Paniculata (500 mg twice, daily) were used. Baseline NK function by standard 4 h 51Cr release assay and TNF alpha and receptor levels were measured by ELISA from resting and phytohemagglutinin (PHA) stimulated adherent and non-adherent Peripheral Blood Mononuclear Cell (PBMC). Total mercaptans and glutathione in plasma were taken and compared to levels measured 6 months later. Complete blood counts and chemistry panels were routinely monitored. As of a mean of 6 months, 16/20 patients were still alive. The 16 survivors had significantly higher NK function than baseline (p < .01 for each) and TNF-alpha levels in all four cell populations studied (p < .01 for each). Total mercaptans (p < .01) and TNF-alpha receptor levels were significantly reduced (p < .01). It was also observed that hemoglobin, hematocrit and glutathione levels were significantly elevated. The only toxicity noted was occasional diarrhea and nausea. The quality of life improved for all survivors by SF-36 form evaluation. An aggressive combination of immunoactive Nutraceuticals was effective in significantly increasing NK function, other immune parameters and hemoglobin from PBMC or plasma in patients with late stage cancers. Nutraceutical combinations may be effective in late stage cancers. Clinical outcomes evaluations are ongoing.

INCREASED TUMOR NECROSIS FACTOR ALPHA AND NK CELL FUNCTION USING AN INTEGRATIVE APPROACH IN LATE STAGE CANCERS
PATIENT DEMOGRAPHICS	PATIENT REGIME INCLUDED	RESULTS AFTER SIX MONTHS
Twenty patients Average age: 49.3 All stage 4 cancers 12 males, 8 females Prognosis from physician: 3.7 months to live	Transfer Factor Plus, Beta Glucans, soy extract, digestive enzymes, vegetarian, low-sugar diet, hyperthermia and more.	Average Tumor Necrosis Factor alpha (TNF) increased from 12.4 to 1287.5 Average increase in NK cell function: 6.4 to 27.6

What is TNF? Click Here to find out!

Click Here to view Dr. See's Peer Review.

Retrospective Study
by Dr. David Markowitz

As a means of introducing myself, let me share some of my background with you. I have been a practicing General Pediatrician for the past 18 years, the last ten of which I have been in Kennebunk Maine. I trained at the University of Connecticut for Medical School, Internship and Residency in Pediatrics, and a Fellowship in Pediatric Hematology/Oncology (childhood cancer). I have encouraged our patient population to use natural products to boost their inherent health and help prevent disease for the past ten years. Most of my knowledge about this natural approach is self-taught, because little if any nutrition or prevention is taught in traditional medical school. Thankfully, this is changing. You are forcing this change because you now demand of your practitioners to learn more as you ask detailed questions of them. (Good for you!)

I joined 4Life™ Research in the summer of 1998 because of my commitment to a natural approach to Health and Wellness and because of my belief in Transfer Factor™ and in the people who lead this Company. This decision has changed my life and the lives of many patients and patient famiies! OUR EARLY PRACTICE EXPERIENCE: We have introduced Transfer Factor™ to over 150 families with now over 200 persons using Transfer Factor™ on a daily basis. I now review the charts of these children on an every two month basis. The facts back up our general impression of greater health and less illness in these children. Effective 2/1/99, we have seen 80% less illness reported to us in these kids and 85% less use of antibiotics, when we compare their histories of last sick season to this year. We will soon match Transfer Factor™ users to like-aged children not using Transfer Factor™ and will report those findings when available. Most of our victories in Health have been "quiet", in that we seem to see these transfer factor kids so rarely. Some of our experience has been absolutely remarkable. To share just one with you, we have a 12 year old girl with Spinal Muscular Atrophy (one of the Jerry Lewis muscular dystrophies), who in previous years has had dozens of serious respiratory diseases requiring repeated use of antibiotics to just keep her alive. She this year has used Transfer Factor™ daily for six months and has required antibiotics just once and has never had a serious chest or respiratory infection. Transfer Factor™ has changed her life! I will share more with you over time.

Addendum 3/13/99: We now have over 210 patients using Transfer Factor™ with continued success. One mother who has Hodgkin's Lymphoma now status post chemo and radiation therapy takes Transfer Factor™ daily: in three months, she has been infection-free with "daily improvement in her health and feeling of well-being" (her words). Her prior history was one with constant respiratory infections due to her severely depressed immune system. Just another quiet victory for Transfer Factor™ and 4Life™ Research. Another interesting observation from our patients: if a child stops taking Transfer Factor™, we have noticed that within 3-6 weeks, this child is in our office with some infection or another. We know that Transfer Factor™ has a half-life of about 3 weeks. This observation then fits what we know from the biologic studies. Parents then reorder the Transfer Factor™ to "never run out". Transfer Factor™ is indeed a science-based product, just as all the 4Life™ Research products are.

Addendum 3/18/99: Another "little success story from Maine": We have a beautiful young boy who has suffered with a rare condition called cellular interstitual pneumonitis with multiple episodes of respiratory diseases over the years. After 4 months of Transfer Factor™ on a daily basis, he has had but one mild upper respiratory infection and no use of antibiotics during one of the worst viral respiratory and flu seasons in southern Maine in a decade. Side effects of Transfer Factor™: NONE. Need I say more! We start our age-matched study of our Transfer Factor™ kids in late April 1999. I will update as data is available.

I am delighted to share with you my appointment to 4 Life Research Medical Advisory Board. We hope to encourage the development of an entire line of children's Health and Wellness products.

Addendum 4/20/99: Just returned from a Wonderful First Leadership Conference. Thank all of you for your kind words and support of children. It is truly heartening to see and feel the commitment. An update as to our kids here locally: review of records show a 79% reduction in reported illness and an 82% reduction in the use of antibiotics. Still truly amazing results with thusfar no untoward side effects. One additional single victory: an 8 year old with Juvenile Rheumatoid Arthritis now on Transfer Factor™ and FibroAMJ™ and in FULL remission for 8 weeks and on no traditional allopathic meds. The quality of this child's life has dramatically improved.

Addendum 4/27/99: A hint of what is coming! During the Leadership Conference, Dr. William Hennen announced the introduction of a second generation Transfer Factor™ product, called Transfer Factor Plus™. This will not replace Transfer Factor™, just augment it's usefulness, by boosting additional components of the immune system in different and possibly more effective ways, particularly in the body's constant battle against bacterial disease and malignancy. This product, just as all the 4LR products, will cure nothing: it rather boosts the body's ability to handle a multitude of health challenges, in this case, via the immune system. Dr. Hennen will share many more details about T-F Plus in the near future on our website. And 4LR has already starting working on the third and fourth generations of Transfer Factor™, each with a promise of greater Health and Wellness!

Addendum 5/5/99: Some wonderful news to share with you. We now have two brothers who carry the diagnosis of Autism, both on Transfer Factor™ for 4 months. Mother reports a dramatic increase in communication skills and much improved interactions with people and decreased "flapping" behavior. She is quietly delighted (holding her breath!). Our age-matched review will start in late 5/99. Will add details as they become available.

Addendum 5/8/99: More great news, this time using Transfer Factor™ in an 8 year old with recurrent leukemia on harsh chemotherapy. Since using Transfer Factor™ the last three months, this young man has has NO untoward side-effects due to chemo and has had no fever episodes requiring admission to hospital and antibiotic use. And he is doing very well with his leukemia as well. Soon he will start on the new T Factors Plus product (June 1999). Will update as progress becomes available.

Addendum 5/15/99: First some quick news: I will be presenting our Transfer Factor™ experience in Philadelphia this coming Saturday, 5/22/99. Hope to see you there. Additional practice news with some early experience with T-Factors +: As a Medical Advisory Board member, I had three bottles of pre-release Transfer Factor Plus™ available to me. We used it in a 6 year old with an antibiotic resistant sinusitis (28 day treatment). Within 36 hours of Transfer Factor Plus™ use, he was TOTALLY CLEAR of congestion, fever, and the thick purulent green nasal discharge had cleared. A 49 year old father of a patient with an undiagnosed mass in his throat and neck: he refused to see his allopathic MD out of fear but wanted to try something "natural". I encouraged him to see his doctor and offered him some Transfer Factor Plus™. After three weeks of use, it has been reduced 80% in size. He is delighted and now has promised to see his doctor for a follow-up. We also have two adults with metastatic malignancy who have started on the product with thusfar no feedback. Will keep all informed of their progress. Total patient load now using Transfer Factor™ is over 250. Have also started the tedious task of an age and sex-matched review of our Transfer Factor™ experience this past sick season. Will have results within the next three months.

Addendum 5/23/99: Early results from the first of four months of study re: age-matching. We have now compared 25% of our 125 kids on Transfer Factor™ to like aged and sexed children in the practice who sis not use Transfer Factor™: Although preliminary in nature, we see a 62% reduction in reported illness and an 85% reduction in reported antibiotic use in those children who used Transfer Factor™ daily. I remind all that this is but 25% of the data, so stay tuned for the remainder over the next 2-3 months. Our first two Transfer Factor Plus™ reports: a 6 year old boy with a 28 day history of antibiotic-resistant sinusitis responded in less than 36 hours of immune boosting with Transfer Factor Plus™ (one cap twice daily). He was symptom-free at 36 hours! Another experience for the books: a 49 year old with an undiagnosed mass (4-5 cm) in his neck and throat of 4 months duration and growth, who refused to see his allopathic MD out of fear. There is no demonstrable mass in this neck/throat after 23 days of immune-boosting with 2 caps of Transfer Factor Plus™ three times daily. He was strongly encouraged to see his MD for diagnosis and follow-up. Thusfar he has refused to do so, but we are still working on him. He continues to promise that he will follow up with his physician. More experience with Transfer Factor Plus™ to follow. Addendum 6/5/99: Our 49 year old father of one of our patients did see his MD and found to have normal exam. Chest X-ray was clear and now remains asymptomatic for 6 weeks on Transfer Factor Plus™. We have now compared 45% of our Transfer Factor™ users to age- and sex-matched patients in the practice for the last 9 months. Still astouding results with 68% less reported illness and 84% less use of antibiotics. We now have used T-Factors Plus in 7 people, 5 with bacterial disease (4 sinusitis and 1 impetigo) and 2 with apparent malignant disease, thusfar with all positive experiences. Total Transfer Factor™ users in the practice number 250 children and many of their parents. We now encourage all of our Transfer Factor™ families and new users to stay on Transfer Factor™ as their immune boosting base and use T-Factors Plus as an additional supplement at times of "stress". Now Transfer Factor™, T-Factors Plus™, and BioVits fill our patient families' "Health and Wellness" cabinet (notice, not a "medicine" cabinet). More later...

Addendum 7/2/99: And now on to our age/sex-matched study. . . I have now completed a retrospective study comparing kids in the Practice who have used Transfer Factor™ consistently for six or more months to same sexed and aged children in the Practice who did not use Transfer Factor™ during the same period. Our computers matched the ages and sexes of the children. All records were reviewed including those of our office, those of cross-covering MD's and the ER and data were compared. The results are indeed remarkable! We found 74% less reported illness and 84% less reported use of antibiotics in the consistent Transfer Factor™ users when compared to non-Transfer Factor™ users. 125 Transfer Factor™ users were reviewed with 87 kids using Transfer Factor™ consistently for six months or more, aged 8 months to 9 years. We are delighted with these results! We will be preparing manuscripts for submission to various medical journals and hopefully, allowing us to share our results with the more traditional allopathic medical world. A T- Factors Plus experience to report: a 37 year old father of 4 children, diagnosed with advanced Hepatitis C, complicated by gastro-esophageal reflux, chronic constipation, severe fatigue, and sleeplessness. After only 2-3 weeks of Transfer Factor Plus™ at 2 caps three times daily, this man reports improved liver function testing (by documented lab testing), NO reflux, much improved bowel function (he has stopped all meds!), and now much improved energy and sleep (6-8 hours nightly). We know that Hep C is an "envelope virus" and with improved immune and complement function with Transfer Factor Plus™ boosting, it would appear that he is now able to better handle this chronic viral infection NATURALLY! Will update you on his condition as time passes. Our 49 year old with the unidentified neck mass continues to be symptom-free and feeling well. More later...

Addendum 7/13/99: People say that Summer is "slow" for networkers. I remind all of you that every day of every month of every season is the right and only time to share these products. And if you think about it, those with Fibro or Chronic Fatigue need us now more than ever. They deserve to feel good during these warm summer months. How about 1-2 months of immune-boosting before the cold weather hits in the Fall. We would all be healthier this coming sick season with 2 months of Transfer Factor™ or Transfer Factor Plus™ on board. Traveling this Summer for vacation? What an extra-ordinary opportunity to share our Mission and Products with people in other areas. Our goal is to get the word out there that people can live Healthier lives. Summer is "slow" if only you choose it to be that way! Now GO FORTH and share our Vision for Health and Wellness. I look forward to meeting many of you in the San Francisco area at the end of the month! Now fill your Health and Wellness Cabinet with Transfer Factor™, Transfer Factor Plus™, and the rest of 4LR products and share them with the rest of the World!
I bid you Peace. Dr. David

The following study was conducted at the Institute of Longevity. The purpose of the study was to examine the synergistic effects of the components of Transfer Factor Plus™. Each component was tested separately and then tested as a whole unit. Together the proprietary blend increased NK Cell functions more than the sum total of all of the ingredients tested separately. This study indicates that the intelligence contained in Transfer Factor™, has an enhancing effect on other nutrients.

In vitro study

Ingredient 10 GM /ml NK Function

PBMC (Control) 25.6%

Zinc 26.8% NS

Proprietary Blend 59.9% <0.02

(Mushrooms etc)

Zinc +Prop. Blend 95.4 <0.01

Transfer Factor™ alone 128.5% <0.01

Complete Prod. (Transfer Factor Plus™) 273.6% <0.01

The sum of the individual product is less than the Complete Product (Transfer Factor Plus™).

There is synergy in having a combination of Transfer Factor Plus™.

Transfer Factor Study with Autistic Children

9 children
ages: 2.9-9.9
average age: 5.07

These children were given three capsules of Transfer Factor, three times daily, for three months. Each patient was assessed prior to the treatment, six weeks into the study, and at the completion of the three-month study. Dr. Bock used the Gilliam Autism Rating Scale for evaluation purposes. This method applies different scores based on: stereotyped "autistic" behaviors, communication, social interaction and developmental markers. These scores are then added together to determine an autism quotient. The higher the autism quotient is, the higher the degree of autism in the patient.

At the end of the three-month study, seven out of the nine autistic children had at least some improvement. Specifically, these improvements included:

• More attentive
• Eye contact improved
• Eczema improved
• Decreased incidence of illness
• Improved language skills
• Resolution of diarrhea
• Improved toileting skills

Although this study was small, Dr. Bock believes its results are very promising. He has included Transfer Factor as part of his treatment protocol and is excited about its possibilities for boosting the immune system in patients with autism as well as many other conditions he encounters on a daily basis.

• Abstracts on studies conducted with transfer factors from bovine colostrum
• Abstracts on studies conducted with transfer factors from blood leukocytes